Click here to create your personal news page. The news that appears on Eisai will appear there and be constantly updated. You can then modify the page, share it with your friends, or export it and have it appear elsewhere.

You can also create a personal news page and follow the news that interests you by clicking on the tab labelled 'New page'.  

topics : related - allExplore

Shopping Categories

  1. 1. Smartphone
  2. 2. Mobile Phone
  3. 3. Digital Camera
  4. 4. Laptop Computer
  5. 5. LCD Monitor
  6. 6. Printer
  7. 7. Graphic Card
  8. 8. GPS
  9. 9. Motherboard
  10. 10. Processor
  11. 11. Digital Camcorder
  12. 12. Desktop Computer
  13. 13. A/V Amplifier
  14. 14. Case
  15. 15. Fan & Accessories

Wikio Shopping

  1. 1. Automotive
  2. 2. Beauty & Fragrances
  3. 3. Car/Motor Bike
  4. 4. Clothing, Accessories & Shoes
  5. 5. Communication
  6. 6. Computers
  7. 7. Electronics
  8. 8. Flowers & Gifts
  9. 9. Gourmet & Foods
  10. 10. Health & Personal Care
  11. 11. Home & Garden
  12. 12. Household Appliances
  13. 13. Jewelry & Watches
  14. 14. Musical Instruments
  15. 15. Sports & Outdoors
  16. 16. Toys & Baby
  17. 17. Video Games

Participate

News Categories



Eisai



Sort by : relevance - date
+Vote!

Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will ...

Life Science World (Free subscription) | yesterday

[NEWS] Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 2 /PRNewswire/ — Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive...

+Vote!

Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017

PR News Wire (Free subscription) | yesterday

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision ResourcesWALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate...

+Vote!

Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study In Platinum-Resistant Ovarian Cancer

Business Wire (Free subscription) | yesterday

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of farletuzumab (also known as MORAb-003).

+Vote!

Humira Will Overtake Remicade as the Crohn's Disease Market Leader By 2012

PR News Wire (Free subscription) | 12/01/2008

WALTHAM, Mass. /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Abbott/Eisai's Humira is poised to overtake Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade as the Crohn's disease market leader by 2012. Humira will retain its leading position through 2017, despite competition from two new TNF-alpha...